Back to top
more

Labcorp (LH)

(Delayed Data from NYSE)

$234.38 USD

234.38
566,922

+5.27 (2.30%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $234.35 -0.03 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Will LabCorp's (LH) Q2 Earnings Gain From Overall Growth?

by Zacks Equity Research

Within Covance Drug Development, LabCorp (LH) is focused on driving profitable growth through expanded solutions and enhanced operational capabilities.

LabCorp (LH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LH vs. CNMD: Which Stock Is the Better Value Option?

by Zacks Equity Research

LH vs. CNMD: Which Stock Is the Better Value Option?

Will Pharmacy International Hit Walgreens (WBA) Q3 Earnings?

by Zacks Equity Research

Challenging market conditions, especially in retail, causes a slowdown in the Retail Pharmacy International division at Walgreens Boots (WBA).

LabCorp Diagnostics Shows Robust Growth Amid Price Declines

by Zacks Equity Research

LabCorp's (LH) Diagnostics business sees an organic uptick in terms of both revenues and volumes in spite of further price reductions.

Zacks.com featured highlights include: Starbucks, T. Rowe Price, Laboratory Corporation, Carlisle and FleetCor

by Zacks Equity Research

Zacks.com featured highlights include: Starbucks, T. Rowe Price, Laboratory Corporation, Carlisle and FleetCor

Swayta Shah headshot

Robust Sales Growth Makes These 5 Stocks Worth Buying Now

by Swayta Shah

Sales growth provides investors an insight into product demand and pricing power.

LH vs. XRAY: Which Stock Is the Better Value Option?

by Zacks Equity Research

LH vs. XRAY: Which Stock Is the Better Value Option?

LabCorp (LH) Closes Envigo Swap Deal, Expands in CRO Space

by Zacks Equity Research

The conclusion of LabCorp's (LH) swap transaction will help enhance the company's Covance global nonclinical drug development capabilities with additional sites and resources.

Why Is LabCorp (LH) Up 1.6% Since Last Earnings Report?

by Zacks Equity Research

LabCorp (LH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

LabCorp Grows on Strong Diagnostics Arm Amid Contract Losses

by Zacks Equity Research

LabCorp's (LH) diagnostics business grows organically despite additional price reductions.

LH or ALGN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

LH vs. ALGN: Which Stock Is the Better Value Option?

Urmimala Biswas headshot

LabCorp (LH) Q1 Earnings Top Mark, Revenues Lag Estimates

by Urmimala Biswas

Despite increasing acquisitions and favorable mix, the disposition of certain businesses and the implementation of PAMA are adversely affecting LabCorp's (LH) growth.

Can Covance Business Growth Aid LabCorp (LH) in Q1 Earnings?

by Zacks Equity Research

Within Covance Drug Development, LabCorp (LH) is expected to drive profitable growth through expanded solutions and enhanced operational capabilities.

LabCorp (LH) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Thermo Fisher (TMO) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Strong analytical instruments business, product portfolio expansion and prudent growth strategy are likely to support Thermo Fisher (TMO) in Q1. However, forex might act as a dampener.

What's in Store for Align Technology (ALGN) in Q1 Earnings?

by Zacks Equity Research

Higher Invisalign case volume, solid show by Clear Aligner segment and anticipated sturdy growth at Scanner and Service business are likely to support Align Technology (ALGN) in Q1. However, operating expenses are likely to act as dampeners.

LabCorp (LH)-QIAGEN Form Alliance in In-Vitro Diagnostics

by Zacks Equity Research

LabCorp's (LH) wide exposure in the companion diagnostics space further enhances QIAGEN's personalized health collaborations with the pharmaceutical bigwigs.

Should Value Investors Consider Laboratory Corporation (LH)?

by Zacks Equity Research

Laboratory Corporation (LH) stock may be a good choice for value-oriented investors right now from multiple angles.

Why Is LabCorp (LH) Down 0.6% Since Last Earnings Report?

by Zacks Equity Research

LabCorp (LH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

LabCorp's (LH) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

LabCorp's (LH) Q4 earnings gain on strength in the Covance Drug Development business.

LabCorp (LH) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

LabCorp (LH) delivered earnings and revenue surprises of 1.61% and 0.15%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Will Diagnostics Business Ail LabCorp (LH) in Q4 Earnings?

by Zacks Equity Research

LabCorp (LH) is likely to gain traction from the company's collaboration with Walgreens.

LabCorp (LH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

LabCorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LabCorp Rides on Covance Business Amid Reimbursement Woes

by Zacks Equity Research

Within Covance Drug Development business, LabCorp (LH) aims at reaping huge profits via expanded solutions and better operational skills.